Annals of Diagnostic Pathology
Volume 11, Issue 1 , Pages 49-54 , February 2007

KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate

  • Tomoko Mitsuhashi, MD, PhD

      Affiliations

    • Department of Pathology, Saitama Medical School, Saitama 350-0495, Japan
    • Corresponding Author InformationCorresponding author. Division of Histopathology, Department of Pathology, Tohoku University Graduate School of Medical Science, Aoba-ward, Sendai, Miyagi 980-8575, Japan. Tel.: +81 22 717 8048; fax: +81 22 717 8053.
    • ,
  • Masato Nakayama, MD

      Affiliations

    • Department of Pathology, Saitama Medical School, Saitama 350-0495, Japan
    • Department of Obstetrics and Gynecology, Saitama Medical School, Saitama 350-0495, Japan
    • ,
  • Shinji Sakurai, MD, PhD

      Affiliations

    • Department of Pathology, Jichi Medical School, Tochigi 329-0498, Japan
    • ,
  • Masaki Fujimura, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Saitama Medical School, Saitama 350-0495, Japan
    • ,
  • Yoshihiko Shimizu, MD, PhD

      Affiliations

    • Department of Pathology, Saitama Medical School, Saitama 350-0495, Japan
    • ,
  • Shinichi Ban, MD, PhD

      Affiliations

    • Department of Pathology, Saitama Medical School, Saitama 350-0495, Japan
    • ,
  • Fumihiro Ogawa, MD

      Affiliations

    • Department of Pathology, Saitama Medical School, Saitama 350-0495, Japan
    • ,
  • Takanori Hirose, MD, PhD

      Affiliations

    • Department of Pathology, Saitama Medical School, Saitama 350-0495, Japan
    • ,
  • Osamu Ishihara, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Saitama Medical School, Saitama 350-0495, Japan
    • ,
  • Michio Shimizu, MD, PhD

      Affiliations

    • Department of Pathology, Saitama Medical School, Saitama 350-0495, Japan

References 

  1. Silverberg SG, Kurman RJ. Endometrial stromal tumors. In:  Rosai J editors. Tumors of the uterine corpus and gestational trophoblastic disease. Fascicle 3. Atlas of tumor pathology. Third series. Washington, DC: Armed Forces Institute of Pathology; 1992;p. 91–111
  2. Amant F, Moerman P, Vergote I. The classification of a uterine sarcoma as ehigh-grade endometrial stromal sarcomaf should be abandoned. Gynecol Oncol. 2004;95:412–418[‘letter’]
  3. In:  Tavassoli FA,  Devilee P editor. World Health Organization classification of tumours. Pathology and genetics of the tumours of the breast and the female genital organs. Lyon: IARC Press; 2002;p. 432
  4. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  5. Henrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692–1703
  6. Kitayama Y, Igarashi H, Sugimura H. Initial intermittent microwave irradiation for fluorescence in situ hybridization analysis in paraffin-embedded tissue sections of gastrointestinal neoplasia. Lab Invest. 2000;80:779–781
  7. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol. 1997;10:720–727
  8. Henrich MC, Corless CL, Duensing A, et al. PDGFRα activating mutation in gastrointestinal stromal tumors. Science. 2003;299:708–710
  9. Wasag B, Debiec-Rychter M, Pauwels P, et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol. 2004;17:889–894
  10. Chiorean MV, Guicciardi ME, Yoon JH, Bronk SF, Kaufmanns SH, Gores GJ. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver Int. 2004;24:687–695
  11. Dobashi Y, Takei N, Suzuki S, et al. Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol. 2004;17:1497–1505
  12. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947–4952
  13. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566
  14. Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate–treated squamous carcinoma cells. J Cell Physiol. 2005;205:218–227
  15. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 2003;11:986–991
  16. Moinfar F, Gogg-Kamerer M, Sommersacher A, Regitnig P, Man YG, Zatloukal K, et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am J Surg Pathol. 2005;29:485–489

PII: S1092-9134(06)00039-6

doi: 10.1016/j.anndiagpath.2006.03.012

Annals of Diagnostic Pathology
Volume 11, Issue 1 , Pages 49-54 , February 2007

Article Tools

* Image Usage & Resolution